1. Home
  2. Companies
  3. CBL
  4. Material Events

Control Bionics (ASX:CBL) — Material Events

ASX:CBL · 18 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Significant 13 articles Notable 4 articles Routine 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
13
Control Bionics Accelerates Growth with 10% Revenue Rise and Expanded US CoverageMedium
Control Bionics reports 10% revenue growth, expands NeuroNode US coverage, advances NeuroStrip rollout, and raises $2.1M
31 Oct 2025 ·Quarterly Activities Report & Appendix 4C ·85
Control Bionics Expands US and European Market Access with New Distribution Deals and Reimbursement MilestonesMedium
Control Bionics advances commercial partnerships and expands market access across assistive tech, sports, and medical sectors
4 June 2026 ·Commercial Update ·85
Control Bionics Secures $10 Million Capital Raise to Fuel Global ExpansionMedium
Control Bionics announces $10 million capital raising via placement and Share Purchase Plan
25 June 2026 ·Capital Raising ·85
Control Bionics Secures $3.8M, Partners with Tobii and Apple BCI, Expands NeuroStrip ReachMedium
Control Bionics raises $3.8M, partners with Tobii and Apple BCI, advances NeuroStrip and NeuroBounce acquisition
28 Jan 2026 ·Quarterly Activities Report & Appendix 4C ·85
Control Bionics Leverages Apple’s BCI Protocol to Revolutionize AAC DevicesMedium
Control Bionics integrates Apple's BCI protocol to enhance AAC device usability and accessibility
11 Nov 2025 ·Product Integration Announcement ·85
Control Bionics Hits Record $7M Revenue, Nears US Distribution DealMedium
Control Bionics posts record FY25 revenue growth, US profitability milestone, and advances NeuroNode and NeuroStrip expansion
31 July 2025 ·Quarterly Activities Report & Appendix 4C ·85
Control Bionics Unlocks German Reimbursement for NeuroNode DeviceMedium
Control Bionics Secures German Statutory Reimbursement Listing for NeuroNode Device
4 Mar 2026 ·Regulatory Approval Announcement ·85
Control Bionics Raises $3.25M to Accelerate Neurotech CommercialisationMedium
Control Bionics raises $3.25M via placement to fund commercial growth
1 Dec 2025 ·Capital Raising ·80
Control Bionics Moves to Full Ownership of NeuroBounce ProgramMedium
Control Bionics to Fully Acquire Neuro Elite Athletics and NeuroBounce Program
3 Dec 2025 ·Acquisition Announcement ·80
Control Bionics Advances Distribution Model and Secures German Reimbursement MilestoneMedium
Control Bionics advances distributor model, secures US partnership, gains German reimbursement, reports $1.2M revenue and $1.7M cash outflow
30 Apr 2026 ·Quarterly Activities Report & Appendix 4C ·75
Control Bionics Launches $2.06M Rights Issue to Accelerate NeuroStrip RolloutMedium
Control Bionics launches $2.06M rights issue to fund NeuroStrip rollout and growth
28 Aug 2025 ·Capital Raising ·75
Control Bionics and Tobii Dynavox Launch US Pilot for NeuroNode DistributionMedium
Control Bionics and Tobii Dynavox launch US pilot for NeuroNode distribution partnership
27 Jan 2026 ·Partnership Announcement ·75
Control Bionics Expands US Reach with PRC-Saltillo NeuroNode DealMedium
Control Bionics inks US distribution deal with PRC-Saltillo for NeuroNode®
29 Jan 2026 ·Distribution Agreement Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.